SynthesisWorld journal of urology2018
Effects of testosterone supplement treatment in hypogonadal adult males with T2DM: a meta-analysis and systematic review.
Synthesis in World journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE).Journal of endocrinological investigation · 2022Guideline
- Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis.The lancet. Healthy longevity · 2022Pooled it
- Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.World journal of urology · 2019Pooled it
- Antioxidants in Menopausal Transition and Male Late-Onset Hypogonadism for the Prevention of Diabetes.Antioxidants (Basel, Switzerland) · 2026Review
- Chronic kidney disease risk assessment: Findings from backward-looking study using annual health check-up data in Japan.Diabetes, obesity & metabolism · 2025Article
- Testosterone therapy for functional hypogonadism in middle-aged and elderly males: current evidence and future perspectives.Hormones (Athens, Greece) · 2024Review
- Treatment with Testosterone Therapy in Type 2 Diabetic Hypogonadal Adult Males: A Systematic Review and Meta-Analysis.Clinics and practice · 2023Review
- Gaps in the management of diabetes in Asia: A need for improved awareness and strategies in men's sexual health.Journal of diabetes investigation · 2022Review
- Effects of Testosterone Replacement Therapy on Glycolipid Metabolism Among Hypogonadal Men withT2DM: A Meta-Analysis And System Review Of Randomized Controlled Trials.Sexual medicine · 2021Review
- An Updated Review: Androgens and Cognitive Impairment in Older Men.Frontiers in endocrinology · 2020Review
- Male Obesity-related Secondary Hypogonadism - Pathophysiology, Clinical Implications and Management.European endocrinology · 2019Review
- Association between outdoor air pollution and semen quality: Protocol for an updated systematic review and meta-analysis.Medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
purposeTestosterone supplement treatment (TST) is a classic therapy for hypogonadal men with type 2 diabetes mellitus (T2DM), but the effects of TST in different studies are inconsistent. We conducted this meta-analysis to evaluate the precise role of TST in hypogonadal men with T2DM.
methodsPubMed, Embase, Cochrane Library and Web of Science were searched to identify qualified randomized controlled trials (RCTs). Pooled mean differences (MDs) with 95% confidence intervals (CIs) were calculated to measure the specific effects of TST. Trial sequential analysis was performed to verify the pooled results.
resultsA total of eight RCTs were enrolled in our meta-analysis, including 596 hypogonadal participants with T2DM. Compared with comparators, TST can significantly improve glycemic control by reducing homeostatic model assessment of insulin resistance (MD - 0.79, 95% CI - 1.23 to - 0.34), fasting glucose (MD - 0.98, 95% CI - 1.13 to - 0.54), fasting insulin (MD - 2.47, 95% CI - 3.99 to - 0.95) and HbA1c% (MD - 0.45, 95% CI - 0.73 to - 0.16). In addition, TST can result in a decline in cholesterol (MD - 0.29, 95% CI - 0.38 to - 0.19) and triglyceride (MD - 0.37, 95% CI - 0.59 to - 0.15).
conclusionOur results indicated that TST can improve glycemic control and decrease TC and TG in hypogonadal patients with T2DM. We recommend TST during the anti-diabetic therapy in these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.